[EN] DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS<br/>[FR] COMPOSITIONS DE DIFLUOROLACTAME DESTINÉES À DES MALADIES ET DES AFFECTIONS OSSEUSES MÉDIÉES PAR EP4
申请人:CAYMAN CHEMICAL CO INC
公开号:WO2014015246A1
公开(公告)日:2014-01-23
Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.
DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS
申请人:Cayman Chemical Company, Inc.
公开号:US20150174099A1
公开(公告)日:2015-06-25
Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I)
or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L
1
, L
2
, L
4
, R
1
, R
4
, R
5
, R
6
, and s are as defined in the specification.
DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
申请人:Cayman Chemical Company, Inc.
公开号:US20150175538A1
公开(公告)日:2015-06-25
Disclosed herein are compounds of formula (I)
and therapeutic methods of treatment with compounds of formula (I), wherein L
1
, L
2
, L
4
, R
1
, R
4
, R
5
, R
6
, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R
1
, R
4
, R
5
, R
6
, and L
1
are as defined herein. Compounds of formula (IA) have been found useful as EP
4
receptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders.
METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH
申请人:CAYMAN CHEMICAL COMPANY, INC.
公开号:US20160158413A1
公开(公告)日:2016-06-09
The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.